ARCHIVES

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 10 | October 26, 2001

Download PDF Visit The Full Archive

Related Articles

Environmental Carcinogenesis Gets 17% Of NCI Budget

February 20, 1976

MDV3100 Improves Survival, Reduces Death Risk by 37%

November 25, 2011

In Brief: Vietti Heads Chairman’s Committee; Chabner Seeks Deputy Candidates; WHO Centers At MSK

December 2, 1988

Broder On FDA: Don’t Blame Them For Doing Their Jobs (They Have To Work At Parklawn)

September 27, 1991

HHS To Determine Feasibility Of CHOP Evaluation

July 24, 1981

MIT Researcher Ingested P-32; NRC Investigating

October 27, 1995